December 5, 2025 7:45am

Although “uncle algo and his electronic trading dwarfs” are smelling profit!!

Financing: Capricor Therapeutics (CAPR pre-open +$10.99 or +3.90% to $26.39) answering my own question about up pricing on Wednesday (+$23.60), PR release DID “announce positive topline results from its pivotal P3 HOPE-3 trial evaluating Deramiocel it’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). CAPR believes these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position … clinical issues in the FDA’s Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval.” However, there are significant execution and regulatory risks around Deramiocel, including shifting FDA guidance and development costs.

Pre-open Signals: 10 Positive and 3 Negative

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Delayed September data on consumer spending and incomes as well as the personal consumption expenditures index <Commerce Dept>. The PCE report will be the 1st one since the record-setting U.S. government shutdown. The University of Michigan will also release its consumer survey for December.

Thursday’s RMi Closing Bell: Staying positive … https://www.regmedinvestors.com/articles/14216

RMi Research Note: Harvard Apparatus GT (OTCQB): Broke … https://www.regmedinvestors.com/articles/13812

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

C&GT sector should be not be without the benefit of doubt through December after last week’s 1 holiday and 4 sessions of gains

Friday: The pre-open Dow futures are UP +0.09% or (+44 points), the S&P futures are UP +0.20% or (+13 points) and the Nasdaq futures are UP +0.36% or (+91 points)

  • Stock futures are inching higher before inflation data, Friday, 12/5
  • European markets are higher,
  • Asia Pacific markets  trade mixed.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -31.96 points or -0.07%, the S&P closed UP +7.40 points or +0.11% while the Nasdaq closed UP +51.044 points or +0.22%
  • Wednesday: The Dow closed UP +408.44 points or +0.86%, the S&P closed UP +20.35 points or +0.30% while the Nasdaq closed UP +40.417 points or +0.17%
  • Tuesday: The Dow closed UP +185.13 points or +0.39%, the S&P closed UP +16.74 points or +0.25% while the Nasdaq closed UP +137.752 points or +0.59%
  • Monday: The Dow closed DOWN -427.06 points or -0.89%, the S&P closed DOWN -36.44 points or -0.53% while the Nasdaq closed DOWN -89.763 points or -0.38%
  • Last week: The S&P 500 increased +4%. the Dow +3% and the Nasdaq jumped 4%.
  • The previous week: The S&P 500 was down -2%, the Dow -2% and the Nasdaq was down -2.7%
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 2 positive and 2 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Pre-open, I take the top 10 and bottom 12 of the previous session's closes to measure the potential of the morning’s possibles ...

AxoGen (AXGN) closed up +$4.52 with a positive +$0.15 or +0.44% preopen

CRISPR Therapeutics (CRSP) closed up +$2.19 after Wednesday’s +$4.41 after Tuesday’s -$0.59 and Monday’s -$1.30 with a positive +$0.21 or +0.36% preopen

Beam Therapeutics (BEAM) closed up +$2.17 after Wednesday’s +$3.37 after Tuesday’s -$0.68 and Monday’s -$1.28 with a positive +$0.24 or +0.83% pre-open

Solid Biosciences (SLDB) closed down +$0.73 with a positive +$0.22 or +3.72% pre-open

Intellia Therapeutics (NTLA +$0.68 with a positive +$0.05 or +0.51% pre-open

Moderna (MRNA) closed up +$0.34 after Wednesday’s +$1.12 with a positive +$0.04 or +0.16 pre-open

Supernus Therapeutics (SUPN) closed up +$0.34 with a negative -$0.10 or -0.22% pre-open

Alnylam Pharmaceuticals (ALNY) closed down -$7.95 after Wednesday’s +$8.36 after Tuesday’s +$10.37 and Monday’s +$3.33 with a positive +$4.43 or +0.95% pre-open

Capricor Therapeutics (CAPR -$4.46 after Wednesday’s +$23.60 with a positive +$1.04 or +4.09% pre-open

uniQure NV (QURE) closed down -$2.74 with a negative -$0.76 or -3.34% pre-open

Arrowhead Pharma (ARWR) closed down -$0.76 after Wednesday’s +$7.12 after Tuesday’s +$1.70 and Monday’s +$3.55 with a positive +$0.04 or +0.06% pre-open

BioNTech (BNTX -$0.72 with a positive +$1.41 or +1.47% pre-open

Lenz Therapeutics (LENZ) closed down -$0.18 with a negative -$0.15 or -0.54% pre-open

 

The BOTTOM LINE: Still feeling the what … anxiety with a small dose/feeling of optimism!

Welcome to my world of defining the “grey’ in our universe!

The cell and gene therapy (C&GT) sector gave back some of last week’s rally

  • Risk-off sentiment has pressured the bull market in recent weeks as worries of persistent inflation, elevated valuations and returns on artificial intelligence spending weigh on investors. <CNBC>

This December week:

  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

Last week, November:

  • 11/28 - Friday closed positive with 29 positive, 10 negative and 1 flat
  • 11/27 – Thursday, a market holiday
  • 11/26 – Wednesday closed positive with 28 positive, 12 negative and 0 flat
  • 11/25 – Tuesday closed positive with 24 positive, 15 negative and 1 flat
  • 11/24 - Monday closed positive with 25 positive, 14 negative and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.